CB terms amended: lower conversion price, higher yield
킵스파마
256940
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2457
Risk-adjusted indicator based on 2457 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Amended Conversion Price: 11,429 KRW/Share (down from 16,328 KRW/Share)
- • Amended Maturity Interest Rate: 7% (up from 0%)
- • Amended Maturity Date: August 13, 2027 (extended from August 13, 2026)
- • Potential Dilution (Amended): 7.21% (down from 10.95%)
- • Remaining Convertible Bond Balance: 16.55B KRW
AI Analysis Summary
Keeps Biopharma Inc. announced an amendment to its convertible bond (CB) terms. The conversion price has been significantly lowered from 16,328 KRW/Share to 11,429 KRW/Share, which is negative for existing shareholders due to increased potential dilution. The maturity interest rate has been raised from 0% to 7%, and the maturity date extended to August 13, 2027. While the potential dilution rate decreased from 10.95% to 7.21% due to a change in the specific CB series being reported, the lower conversion price for the remaining 16.55B KRW CBs still poses a dilution risk. The funds from the original CB issuance were used for acquiring securities in other companies (27B KRW) and operating expenses (5B KRW).
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.